Congenital heart disease (CHD) is one of the most common birth defects, but the full extent of its genetic underpinnings has ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that it will share results from the DEFINE-HT study in a late-breaking oral presentation at the ...

A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

A breakthrough in safely delivering therapeutic DNA to cells could transform treatment for millions suffering from common chronic diseases like heart disease, diabetes, and cancer.

Me’s weekend bankruptcy filing has ignited concerns among consumers who provided the company with their genetic information, and reignited discussions on data privacy among policymakers and se | ...

MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp (a) inhibitor from China's Jiangsu Hengrui ...

More than ever, people are looking to understand their bodies better and take control of their health, but with busy ...

Tenaya Therapeutics (TNYA) announced the publications of positive preclinical data for TN-201, the company’s gene therapy candidate for Myosin-Binding Protein C3-associated hypertrophic cardiomyopathy ...

According to the company’s U.S. privacy statement, if 23andMe is involved in a “bankruptcy, merger, acquisition, ...

PHILADELPHIA- A breakthrough in safely delivering therapeutic DNA to cells could transform treatment for millions suffering from common chronic ...

For this, you have to go to your account there and then go to ‘Settings’. Now simply scroll to ‘23andMe data’ and click on ‘View’. Now choose to ‘Delete Data’ and then ‘Permanently Delete Data’.